Oxford university in trials for blood tests to diagnose dementia
A multi-million pound programme is supported by the Alzheimer’s Society
A country-wide trial aiming to revolutionise how dementia is diagnosed using blood tests is now underway.
Research teams at the University of Oxford are part of the Blood Biomarker Challenge – a multi-million pound programme supported by the Alzheimer’s Society.
The Blood Biomarker Challenge research teams will build on recent breakthroughs in dementia blood tests, generating the evidence needed for them to be used in the NHS to improve diagnosis of dementia.
Team members will assess multiple new and existing blood tests, looking at a range of dementia types including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. The researchers will also look at whether the blood tests can help detect these diseases at various stages and if the results need to be interpreted differently in people from different ethnic backgrounds or with other health conditions such as kidney disease.
Professor Vanessa Raymont, Associate Director, Dementias Platform UK and Senior Clinical Researcher, University of Oxford, said:
“We’re in an incredibly exciting time for dementia research right now, with new drugs that can slow early Alzheimer’s disease. Although these are not yet approved for use in the NHS, we urgently need to revolutionise the way we diagnose people in this country - it will be nothing short of disastrous if people are unable to get a diagnosis early enough to benefit from the new drugs, once they do become available. In addition, many people now want and need the more accurate diagnosis blood biomarkers could provide.
“Blood biomarker tests could be the answer to this problem and the good news is that the technology already exists. What we’re missing is the proof that they really do work in a real-world setting. Our team will be looking at a range of blood tests and we’ll be recruiting participants from a broad range of people including those from minority ethnic groups, the very elderly and people with other medical conditions. This will show us how the blood tests perform in different UK populations.”
Stephanie Everill, 67 from Abingdon in Oxfordshire, said:
“I was diagnosed with Mild Cognitive Impairment about a year ago. My mum had Alzheimer’s, so it’s something I’ve seen firsthand. The scans I had at the hospital showed that my condition is leaning towards Alzheimer’s disease, but I haven’t had that diagnosed officially yet. I’m getting quite forgetful, and I hope that taking part in this study might mean a faster diagnosis and access to treatments for myself and others in the future”.
Dr Sheona Scales, Director of Research at Alzheimer’s Research UK, said:
“Dementia is the leading cause of death in the UK, yet our loved ones can be left anxiously waiting for up to a year for a dementia diagnosis, and even longer in deprived areas.
“The way dementia is diagnosed has barely changed for nearly two decades and requires an urgent rehaul. This has become even more critical as we look to a more hopeful future in which dementia becomes a treatable condition.
“Blood tests are showing great promise and they’re quicker, cheaper and easier to administer than current tests. So, it’s incredibly exciting to see the first steps happening with the Blood Biomarker Challenge, which is set to move the dial on dementia diagnosis, giving people the answers they desperately need.”
Professor Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, said:
“Around one million people in the UK are living with dementia, but a third of these have not received a diagnosis. This is despite us knowing that an early and accurate diagnosis is key to ensuring everyone has access to the treatment, care and support they deserve.
“Blood testing offers the potential to revolutionise dementia diagnosis in the future, so it’s incredibly exciting to see this project coming to life. I’ve spent decades working in science and the NHS, and it really does feel like we’re making progress in the way we treat dementia in this country but we can only treat people once they have that all-important diagnosis. This crucial bit of research is getting us closer than we’ve ever been before.”